Week In Review: Allgenesis Posts Positive Data From US Trial Of Bi-Specific For Diabetic Macular Edema
May 27, 2023 at 15:10 PM EDT
Taiwan’s Allgenesis Biotherapeutics reported positive early data from a US Phase IIa trial of a bi-specific Fc-fusion protein designed to block VEGFs and integrins for Diabetic Macular Edema.
